Re: Merck's PIII Prostate trial, not the one with ZEN-3694, is halted for not showing improvement vs control
posted on
Jan 29, 2023 11:16AM
Zenith's BET Inhibitor ZEN-3694 is Currently Being Evaluated in Multiple Oncology Clinical Trials
I do also agree Zenith might get a larger partnership or cvr deal this year as well.
I would consider a CVR deal to be a disaster. Years more waiting with no visibility. And acquiring pharmas do their best to minimize or avoid any future payments. There have been several lawsuits from unhappy shareholders.